Platelet cut-off for anticoagulant therapy in thrombocytopenic patients with blood cancer and venous thromboembolism: an expert consensus.
Napolitano M, Saccullo G, Marietta M, Carpenedo M, Castaman G, Cerchiara E, Chistolini A, Contino L, De Stefano V, Falanga A, Federici AB, Rossi E, Santoro R, Siragusa S; Gruppo Italiano Malattie EMatologiche dell’Adulto (GIMEMA) Working Party on Thrombosis and Hemostasis; Gruppo Italiano Malattie Ematologiche dell’Adulto (GIMEMA) Working Party on Thrombosis and Haemostasis (see Appendix 1); De Stefano V, Falanga A, Tosetto A, Avvisati G, Carpenedo M, Federici AB, Marietta M, Napolitano M, Rossi E, Santoro C, Castaman G, Cerchiara E, Chistolini A, Contino L, Mazzucconi MG, Nichele I, Russo L, Santi R, Santoro RC, Siragusa S, Tagariello G.
Napolitano M, et al.
Blood Transfus. 2019 May;17(3):171-180. doi: 10.2450/2018.0143-18. Epub 2018 Oct 24.
Blood Transfus. 2019.
PMID: 30418130
Free PMC article.
Review.
RESULTS: In acute VTE, the panel suggests safe anticoagulation with LMWH at therapeutic doses for PLT between 50<10010(9)/L and at 50% dose reduction for PLT 30<5010(9)/L. In acute VTE for PLT <3010(9)/L, the following interventions are recommended: …
RESULTS: In acute VTE, the panel suggests safe anticoagulation with LMWH at therapeutic doses for PLT between 50<10010(9)/L and at …